Lannett Comes Out Firing On Insulin Pipeline Prospects
US-Based Player Needs Big Launches To Reverse Depleted P&L Trend
Lannett continued to talk up its prospects of launching numerous low-competition, high-value products in the coming years – as it disclosed another sizeable loss for its 2022/23 financial year.
